Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months) · hypericum perforatum
Hypericum perforatum extract (Sardella 2008, the only low-risk-of-bias study) contributes to the dietary supplements short-term symptom-relief comparison (insufficient/contradictory); no separate estimate reported.
1 study · 43 participants
GRADE not reported
Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
QoL · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months) · hypericum perforatum
Sardella 2008 (43 participants) evaluated QoL from patient self-reports and narratively indicated that both intervention and placebo participants were better able to cope at trial completion.
1 study · 43 participants
GRADE not reported
Change in feeling of dryness · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
QoL · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether dietary supplements (lycopene) changes change in quality of life (QoL) compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: euphoric behaviour · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether benzodiazepines (topical clonazepam) changes adverse effects: euphoric behaviour compared with placebo (very low certainty).
1 finding from 1 review
Change in taste · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months) · topical urea 10%
SoF9. Change in taste short-term (Quantitative Sensory Testing gustative threshold): single study narratively reported no difference in short-term gustation thresholds; 38 participants (1 RCT, topical urea); very low.
1 study · 38 participants
Very low
Change in feeling of dryness · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
Removal of predisposing habits (e.g. tobacco/alcohol cessation) vs Placebo or no treatment
Outcome not reported · People with a diagnosis of oral leukoplakia
The review found no eligible studies for this question.
1 finding from 1 review
QoL · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether physical barriers (tongue protector) changes change in quality of life (QoL) compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: headache · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether dietary supplements (alpha lipoic acid +/- adjunctive ingredients) changes adverse effects: headache compared with placebo (very low certainty).
1 finding from 1 review
Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
SoF 1, Safety of the intervention at 4 to 12 months: '3 studies (1 each evaluating topical acitretin, topical 13-cis-retinoic acid, 200,000 IU per week of vitamin A) found no adverse effects. Systemic 13-cis-retinoic…
4 studies
GRADE not reported
Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
Adverse effects · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
Change in QoL - depression (surrogate marker) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether physical barriers (tongue protector) changes change in QoL - depression (surrogate marker) compared with placebo (very low certainty).
1 finding from 1 review
Change in feeling of dryness · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
Change in QoL - anxiety (surrogate marker) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether dietary supplements (lycopene) changes change in QoL - anxiety (surrogate marker) compared with placebo (very low certainty).
1 finding from 1 review
Change in taste · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
Change in feeling of dryness · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review